Argent BiopharmaRGTLF Debt-to-EBITDA is -1.56 as of Dec. 2025. The stock has 8 warning signs investors should review. Among 687 Drug Manufacturers companies, Argent Biopharma ranks worse than 145560.26% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Argent Biopharma's Debt-to-EBITDA or its related term are showing as below:
RGTLF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.08 Med: -0.1 Max: 0
Current: -1.08
RGTLF's Debt-to-EBITDA is ranked worse than 100% of 687
companies
in the Drug Manufacturers industry
Industry Median: 1.65
vs RGTLF: -1.08
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Argent Biopharma Debt-to-EBITDA Related Terms
Argent Biopharma Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Argent Biopharma's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Argent Biopharma's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Argent Biopharma Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Argent Biopharma's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Argent Biopharma's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Argent Biopharma (RGTLF) has a Debt-to-EBITDA of -1.56 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Argent Biopharma. According to the industry distribution chart, Argent Biopharma ranks #999999 out of 687 companies in the Drug Manufacturers industry.
Is Argent Biopharma's Debt-to-EBITDA too high?
Argent Biopharma's current Debt-to-EBITDA is -1.56. Based on the distribution chart, Argent Biopharma ranks #999999 out of 687 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Argent Biopharma's Debt-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Argent Biopharma ranks #999999 out of 687 companies for Debt-to-EBITDA. This places Argent Biopharma in the lower half of its industry. The industry median Debt-to-EBITDA is 1.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.65, based on 687 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Argent Biopharma. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Argent Biopharma's current Debt-to-EBITDA is -1.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Argent Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Argent Biopharma (RGTLF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.02, compared to a current price of $0.03 — trading 25% above its estimated fair value. The current Debt-to-EBITDA is -1.56. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Argent Biopharma (RGTLF), the current Debt-to-EBITDA is -1.56 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Argent Biopharma Ltd is a clinical-stage biopharmaceutical company pioneering nano-engineered therapeutics that reset the balance between the nervous and immune systems. Its assets, CannEpil and CimetrA, target immune dysregulation in drug-resistant epilepsy and cytokine-driven inflammatory disorders, respectively. The products of the company include CannEpil for refractory epilepsy and cerebral palsy, CimetrA for acute lung injury and ARDS, and CogniCann for enhancing the quality of life in dementia and Alzheimer's patients, with additional treatments in development, and others. Its geographic areas are Malta, Slovenia and others, and Australia. The group generates the majority of its revenue from Slovenia and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGTLF has been successfully added to your 